I-131-chTNT-mediated radioimmunotherapy for non-uptaking I-131 pulmonary metastases from differentiated thyroid carcinoma

作者：Gao Shi; Ji Tiefeng; Wen Qiang; Chen Bin; Ma Qingjie; Chen Zuowei; Liu Lin^*

来源：NUCLEAR SCIENCE AND TECHNIQUES, 2013, 24(6): 060302.

• I-131-chTNT
• Pulmonary metastases
• Differentiated thyroid carcinoma
• Micronucleus

In this paper, the safety and efficacy of I-131-labeled mouse/human chimeric monoclonal antibody (I-131-chTNT)-mediated radioimmunotherapy are evaluated because the patients have non-uptaking I-131 pulmonary metastases from differentiated thyroid carcinoma (DTC). The 16 patients were injected intravenously by 29.6 +/- 3.7 MBq.kg(-1) using I-131-chTNT. The chest computer tomography was performed before treatment, as well as 28 and 70 days after treatment. Responses and safety were assessed during the treatment. The results show that the I-131-chTNT infusion was well tolerated with the 12.5% complete response, 18.8% partial response, 25.0% progressive disease, and the 43.8% stable disease, indicating that most treatment-related adverse effects are mild transient and reversible. The I-131-chTNT is promising for patients with non-uptaking the I-131 pulmonary metastases from DTC.

• 单位
  吉林大学